메뉴 건너뛰기




Volumn 10, Issue 3 SUPPL., 2004, Pages

Prostaglandins: Modulators of inflammation and cardiovascular risk

Author keywords

Cardiovascular risk; COX; Coxibs; Cyclooxygenase; Hypertension; NSAIDs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE A2; THROMBOXANE B2; VALDECOXIB;

EID: 3042588401     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000130685.73681.8b     Document Type: Conference Paper
Times cited : (18)

References (48)
  • 1
    • 0034971264 scopus 로고    scopus 로고
    • Why there are two cyclooxygenase isozymes
    • Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
    • (2001) J Clin Invest , vol.107 , pp. 1491-1495
    • Smith, W.L.1    Langenbach, R.2
  • 2
    • 3042564321 scopus 로고    scopus 로고
    • Prostaglandins, aspirin and other NSAIDs
    • Goldman L, Ausiello D, eds. London: Elsevier Science
    • FitzGerald GA. Prostaglandins, aspirin and other NSAIDs. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. London: Elsevier Science; 2004:155-161.
    • (2004) Cecil Textbook of Medicine, 22nd Ed. , pp. 155-161
    • FitzGerald, G.A.1
  • 3
    • 0037108979 scopus 로고    scopus 로고
    • COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
    • Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926-13931.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 13926-13931
    • Chandrasekharan, N.V.1    Dai, H.2    Roos, K.L.3
  • 4
    • 0034931501 scopus 로고    scopus 로고
    • Genetic and pharmacological analysis of prostanoid receptor function
    • Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
    • (2001) J Clin Invest , vol.108 , pp. 25-30
    • Narumiya, S.1    FitzGerald, G.A.2
  • 5
    • 0034527045 scopus 로고    scopus 로고
    • The fight against rheumatism: From willow bark to COX-1 sparing drugs
    • Vane JR. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol. 2000;51(4 Pt 1):573-586.
    • (2000) J Physiol Pharmacol , vol.51 , Issue.4 PART 1 , pp. 573-586
    • Vane, J.R.1
  • 6
    • 0036083196 scopus 로고    scopus 로고
    • COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice
    • Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002;122:1913-1923.
    • (2002) Gastroenterology , vol.122 , pp. 1913-1923
    • Sigthorsson, G.1    Simpson, R.J.2    Walley, M.3
  • 7
    • 0033577982 scopus 로고    scopus 로고
    • Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
    • Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899 [Published erratum appears in N Engl J Med. 1999;341:548].
    • (1999) N Engl J Med , vol.340 , pp. 1888-1899
    • Wolfe, M.M.1    Lichtenstein, D.R.2    Singh, G.3
  • 8
    • 0033577982 scopus 로고    scopus 로고
    • Published erratum appears
    • Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899 [Published erratum appears in N Engl J Med. 1999;341:548].
    • (1999) N Engl J Med , vol.341 , pp. 548
  • 9
    • 0035112660 scopus 로고    scopus 로고
    • Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient
    • Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology. 2001;120:594-606.
    • (2001) Gastroenterology , vol.120 , pp. 594-606
    • Laine, L.1
  • 10
    • 0242690224 scopus 로고    scopus 로고
    • COX-2 and beyond: Approaches to prostaglandin inhibition in human disease
    • FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
    • (2003) Nat Rev Drug Discov , vol.2 , pp. 879-890
    • FitzGerald, G.A.1
  • 11
    • 0035833502 scopus 로고    scopus 로고
    • The coxibs, selective inhibitors of cyclooxygenase-2
    • FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
    • (2001) N Engl J Med , vol.345 , pp. 433-442
    • FitzGerald, G.A.1    Patrono, C.2
  • 12
    • 0034707105 scopus 로고    scopus 로고
    • Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
    • Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
    • (2000) N Engl J Med , vol.343 , pp. 1520-1528
    • Bombardier, C.1    Laine, L.2    Reicin, A.3
  • 13
    • 0036606889 scopus 로고    scopus 로고
    • Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    • Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287-1288.
    • (2002) BMJ , vol.324 , pp. 1287-1288
    • Juni, P.1    Rutjes, A.W.2    Dieppe, P.A.3
  • 14
    • 0034644396 scopus 로고    scopus 로고
    • Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
    • Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
    • (2000) JAMA , vol.284 , pp. 1247-1255
    • Silverstein, F.E.1    Faich, G.2    Goldstein, J.L.3
  • 15
    • 0141962671 scopus 로고    scopus 로고
    • Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial
    • Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford). 2003;42:1207-1215.
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 1207-1215
    • Pavelka, K.1    Recker, D.P.2    Verburg, K.M.3
  • 16
    • 0041571903 scopus 로고    scopus 로고
    • The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events
    • Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am Gastroenterol. 2003;98:1725-1733.
    • (2003) Am Gastroenterol , vol.98 , pp. 1725-1733
    • Hunt, R.H.1    Harper, S.2    Watson, D.J.3
  • 17
    • 0037065502 scopus 로고    scopus 로고
    • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
    • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86 [Published erratum appears in BMJ. 2002;324:141].
    • (2002) BMJ , vol.324 , pp. 71-86
  • 18
    • 0037065502 scopus 로고    scopus 로고
    • Published erratum appears
    • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86 [Published erratum appears in BMJ. 2002;324:141].
    • (2002) BMJ , vol.324 , pp. 141
  • 19
    • 0037442069 scopus 로고    scopus 로고
    • Parsing an enigma: The pharmacodynamics of aspirin resistance
    • FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542-544.
    • (2003) Lancet , vol.361 , pp. 542-544
    • FitzGerald, G.A.1
  • 20
    • 0033524421 scopus 로고    scopus 로고
    • Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
    • McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 272-277
    • McAdam, B.F.1    Catella-Lawson, F.2    Mardini, I.A.3
  • 21
    • 0037134011 scopus 로고    scopus 로고
    • Role of prostacyclin in the cardiovascular response to thromboxane A2
    • Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
    • (2002) Science , vol.296 , pp. 539-541
    • Cheng, Y.1    Austin, S.C.2    Rocca, B.3
  • 22
    • 0030816051 scopus 로고    scopus 로고
    • Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
    • Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678-682.
    • (1997) Nature , vol.388 , pp. 678-682
    • Murata, T.1    Ushikubi, F.2    Matsuoka, T.3
  • 24
    • 0023137593 scopus 로고
    • Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
    • Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186.
    • (1987) Blood , vol.69 , pp. 180-186
    • Reilly, I.A.1    FitzGerald, G.A.2
  • 25
    • 0035924765 scopus 로고    scopus 로고
    • Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    • Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
    • (2001) N Engl J Med , vol.345 , pp. 1809-1817
    • Catella-Lawson, F.1    Reilly, M.P.2    Kapoor, S.C.3
  • 26
    • 0042416748 scopus 로고    scopus 로고
    • Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs
    • Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191-1195.
    • (2003) Circulation , vol.108 , pp. 1191-1195
    • Kurth, T.1    Glynn, R.J.2    Walker, A.M.3
  • 27
    • 0037442182 scopus 로고    scopus 로고
    • Effect of ibuprofen on cardioprotective effect of aspirin
    • MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;3361:573-574.
    • (2003) Lancet , vol.3361 , pp. 573-574
    • MacDonald, T.M.1    Wei, L.2
  • 28
    • 0344005434 scopus 로고    scopus 로고
    • Aspirin, ibuprofen, and mortality after myocardial infarction: Retrospective cohort study
    • Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ. 2003;327:1322-1323.
    • (2003) BMJ , vol.327 , pp. 1322-1323
    • Curtis, J.P.1    Wang, Y.2    Portnay, E.L.3
  • 29
    • 0037368116 scopus 로고    scopus 로고
    • Rofecoxib exerts no effect on platelet plug formation in healthy volunteers
    • Homoncik M, Malec M, Marsik C, et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol. 2003;21:229-231.
    • (2003) Clin Exp Rheumatol , vol.21 , pp. 229-231
    • Homoncik, M.1    Malec, M.2    Marsik, C.3
  • 30
    • 0033665248 scopus 로고    scopus 로고
    • Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
    • Leese P, Hubbard R, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
    • (2000) J Clin Pharmacol , vol.40 , pp. 124-132
    • Leese, P.1    Hubbard, R.2    Karim, A.3
  • 31
    • 0037568022 scopus 로고    scopus 로고
    • Characterization of etoricoxib, a novel, selective COX-2 inhibitor
    • Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol. 2003;43:573-585.
    • (2003) J Clin Pharmacol , vol.43 , pp. 573-585
    • Dallob, A.1    Hawkey, C.J.2    Greenberg, H.3
  • 32
    • 0036289132 scopus 로고    scopus 로고
    • Valdecoxib does not impair platelet function
    • Leese PT, Talwalker S, Kent JD, et al. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275-281.
    • (2002) Am J Emerg Med , vol.20 , pp. 275-281
    • Leese, P.T.1    Talwalker, S.2    Kent, J.D.3
  • 33
    • 0037407092 scopus 로고    scopus 로고
    • The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: Results of a randomized controlled trial
    • Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol. 2003;43:504-513.
    • (2003) J Clin Pharmacol , vol.43 , pp. 504-513
    • Leese, P.T.1    Recker, D.P.2    Kent, J.D.3
  • 34
    • 0035807799 scopus 로고    scopus 로고
    • A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
    • Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A. 2001;98:14583-14588.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 14583-14588
    • Ouellet, M.1    Riendeau, D.2    Percival, M.D.3
  • 35
    • 0034943759 scopus 로고    scopus 로고
    • Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis
    • McEntegart A, Capell HA, Creran C, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 2001;40:640-644.
    • (2001) Rheumatology , vol.40 , pp. 640-644
    • McEntegart, A.1    Capell, H.A.2    Creran, C.3
  • 36
    • 0037149297 scopus 로고    scopus 로고
    • Relative risk of cardiovascular events in patients with rheumatoid arthritis
    • DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol. 2002;89:33D-8D.
    • (2002) Am J Cardiol , vol.89
    • DeMaria, A.N.1
  • 37
    • 12144290072 scopus 로고    scopus 로고
    • Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
    • Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468-1471.
    • (2004) Circulation , vol.109 , pp. 1468-1471
    • Capone, M.L.1    Tacconelli, S.2    Sciulli, M.G.3
  • 38
    • 0037635061 scopus 로고    scopus 로고
    • Efficacy and safety of the cyclooxygenase 2 inhibitors paracoxib and valdecoxib in patients undergoing coronary artery bypass surgery
    • Ott E, Nussmeier NA, Duke PC, et al. ., for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors paracoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481-1492.
    • (2003) J Thorac Cardiovasc Surg , vol.125 , pp. 1481-1492
    • Ott, E.1    Nussmeier, N.A.2    Duke, P.C.3
  • 39
    • 2642538969 scopus 로고    scopus 로고
    • Lumiracoxib (Novartis)
    • Ding C, Jones G. Lumiracoxib (Novartis). IDrugs. 2002;5:1168-1172.
    • (2002) IDrugs , vol.5 , pp. 1168-1172
    • Ding, C.1    Jones, G.2
  • 40
    • 0142120428 scopus 로고    scopus 로고
    • Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program
    • Weir MR, Sperling RS, Reicin A, et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146:591-604.
    • (2003) Am Heart J , vol.146 , pp. 591-604
    • Weir, M.R.1    Sperling, R.S.2    Reicin, A.3
  • 41
    • 0041562646 scopus 로고    scopus 로고
    • Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib
    • White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003;92:411-418.
    • (2003) Am J Cardiol , vol.92 , pp. 411-418
    • White, W.B.1    Faich, G.2    Borer, J.S.3
  • 42
    • 0028580588 scopus 로고
    • Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
    • Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
    • (1994) Ann Intern Med , vol.121 , pp. 289-300
    • Johnson, A.G.1    Nguyen, T.V.2    Day, R.O.3
  • 43
    • 0031983792 scopus 로고    scopus 로고
    • NSAIDs and blood pressure. Clinical importance for older patients
    • Johnson AG. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging. 1998;12:17-27.
    • (1998) Drugs Aging , vol.12 , pp. 17-27
    • Johnson, A.G.1
  • 44
    • 0036308753 scopus 로고    scopus 로고
    • Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II
    • Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69 [Published erratum appears in J Clin Invest. 2002;110:419].
    • (2002) J Clin Invest , vol.110 , pp. 61-69
    • Qi, Z.1    Hao, C.M.2    Langenbach, R.I.3
  • 45
    • 0036321987 scopus 로고    scopus 로고
    • Published erratum appears
    • Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69 [Published erratum appears in J Clin Invest. 2002;110:419].
    • (2002) J Clin Invest , vol.110 , pp. 419
  • 46
    • 0036300898 scopus 로고    scopus 로고
    • The choreography of cyclooxygenases in the kidney
    • FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest. 2002;110:33-34.
    • (2002) J Clin Invest , vol.110 , pp. 33-34
    • FitzGerald, G.A.1
  • 47
    • 1042268032 scopus 로고    scopus 로고
    • Cyclooxygenase-2 expression and inhibition in atherothrombosis
    • Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246-255.
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , pp. 246-255
    • Cipollone, F.1    Rocca, B.2    Patrono, C.3
  • 48
    • 0035853050 scopus 로고    scopus 로고
    • Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
    • Pratico D, Tillmann C, Zhang Z, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 3358-3363
    • Pratico, D.1    Tillmann, C.2    Zhang, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.